Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation

Table 1 Comparison of baseline characteristics between the peptide receptor radionuclide therapy group and control group, mean ± SD/n (%)

	PRRT group (n = 7)	Control group (n = 8)	P value
Gender			1.000
Male	4 (57.1)	5 (62.5)
Female	3 (42.9)	3 (37.5)
Age at LT (years)	43.43 ± 10.24	57.38 ± 9.93	0.019a
Primary tumor			1.000
Lung	0 (0.00)	1 (12.5)
Pancreas	3 (42.9)	4 (50.0)
Rectum	4 (57.1)	3 (37.5)
Ki-67 index (%)	9.43 ± 5.29	14.13 ± 8.56	0.232
SSTR positive	7 (100.0)	8 (100.0)	1.000
Pre-LT liver tumor volume (%)	76.43 ± 15.20	80.00 ± 9.26	0.586
Time to recurrence after LT (months), median (IQR)	3 (3-6.5)	9 (3-12)	0.220
Recurrent site			0.806
Lymph nodes	7 (100.0)	7 (87.5)
Bone	7 (100.0)	8 (100.0)
Intracranial	1 (14.3)	1 (12.5)
Kidney	1 (14.3)	0 (0.0)
Liver	2 (28.6)	0 (0.0)
Combined long-acting octreotide	7 (100.0)	8 (100.0)	1.000
Treatment efficacy			0.110
Complete response	0 (0.0)	0 (0.0)
Partial response	1 (14.3)	0 (0.0)
Stable disease	5 (71.4)	3 (37.5)
Progressive disease	1 (14.3)	5 (62.5)
Overall response rate (%)	14.3	0.0	0.467
Disease control rate (%)	85.7	37.5	0.119

^aP < 0.05.

Group comparisons: Age was compared using the independent-samples t test; Ki-67 index and pre-transplant liver tumor volume percentage were compared using the t-test; Time to recurrence was compared using the Mann-Whitney U test; Categorical variables were compared using Fisher’s exact test (due to small sample size). LT: Liver transplantation; PRRT: Peptide receptor radionuclide therapy; SSTR: Somatostatin receptor; IQR: Interquartile range.